Crucell « Terug naar discussie overzicht

CRUCELL EN DSM SLUITEN PER.C6 OVEREENKOMST ME

24 Posts, Pagina: « 1 2 | Laatste

Omlaag ↓

[verwijderd] 20 augustus 2005 14:50

Er schijnt as maandag een 'bijzondere' aandeelhoudersvergadering te zijn van DSM (Elsevier agenda). Iemand die hier iets meer over weet?

W.

[verwijderd] 20 augustus 2005 15:12

Helaas soldaat, het gaat hier om een splitsing van de aandelen DSM (1:2)
nog prettig weekend, groet CV

[verwijderd] 7 mei 2006 08:31

Clinical Trials

Hepatitis C vaccine trial begins soon
Thu 04 May 2006 02:08 PM CST
MISSOURI (myDNA News)

Human clinical trials involving investigational vaccines to prevent hepatitis C are rare. In recent years, both Saint Louis University's (SLU) Center for Vaccine Development and Johns Hopkins School of Medicine conducted small studies.

A new trial — much larger than the two earlier studies — is about to start at SLU. Two hundred volunteers are needed. SLU is the only site in the United States conducting this study.

"Sixteen years ago, the hepatitis C virus had not even been identified, and now there are an estimated 170 million people around the world infected," said Sharon Frey, M.D., professor of internal medicine in the division of infectious disease at Saint Louis University School of Medicine. "It is critical that we develop a vaccine to combat this growing health problem."

The purpose of this research is to study the safety and effectiveness of Chiron Corp.'s investigational hepatitis vaccine. Although the Chiron vaccine has been given to people in previous studies, this is the first time the vaccine will be tested in humans with a different "adjuvant." (A vaccine adjuvant is a chemical designed to help the body make a better response to the vaccine.) Volunteers will be randomly assigned to receive one of the nine different combinations of hepatitis C virus vaccine and adjuvant.

"Officials at the Centers for Disease Control and Prevention believe that approximately 40,000 new cases of hepatitis C infections occur every year," Frey said. "Therefore, a vaccine to prevent the infection would be an important breakthrough in controlling the spread of the hepatitis C virus."

The study is being conducted by SLU's Center for Vaccine Development (led by the division of infectious diseases and immunology) in collaboration with SLU's Liver Center (led by the school's division of gastroenterology and hepatology). This research is sponsored by the National Institutes of Health and Chiron Corp.

Hepatitis C virus is a blood-borne infection that causes approximately 10,000 deaths annually and is responsible for almost half of the 4,000 liver transplants each year. The CDC estimates medical and work-loss costs for hepatitis C at more than $600 million annually, excluding the costs of transplantation. It is believed that 2.7 million Americans have chronic infection with this virus.

Potential volunteers in this study should call the Saint Louis University Center for Vaccine Development at (314) 977-6333 or e-mail vaccine@slu.edu.
www.mydna.com/resources/clintrial/new...

[verwijderd] 7 mei 2006 09:46

Mooi begin van een stralende zondag, Flosz, ook al zullen de trials de nodige tijd vergen. Ik was net in de VS en zag hoe er wordt gewerkt om de publieke alertheid m.b.t Hep C te vergroten. In New York overal posters met mannen met verminkte gezichten en de tekst "If Hep C was attacking your face instead of your liver, you’d do something about it.”
Alleen al in de VS worden er tegen 2015 30.000 doden per jaar verwacht.

24 Posts, Pagina: « 1 2 | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX 922,75 +8,78 +0,96% 19 mrt


Germany40^	23.317,80	+0,13%
BEL 20	4.499,43	-0,01%
Europe50^	5.513,00	+0,10%
US30^	41.975,80	0,00%
Nasd100^	19.732,80	0,00%
US500^	5.677,02	0,00%
Japan225^	37.865,10	0,00%
Gold spot	3.051,38	+0,04%
EUR/USD	1,0911	-0,27%
WTI	67,05	0,00%